KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial).

Manjula Singh, Sindhu Joshi, Vikram Vohra, Rohit Sarin, Suchit Vasant Kamble, Banurekha Velayutham, Anant Mohan, Urvashi B Singh, Rakesh Kumar, Sanghamitra Pati, Manoranjan Pattnaik, Prasanta Raghab Mohapatra, Uma Shankar, Somashekar Narasimhaiah, Geeta Yadav, Syed Hissar, Rashmi Rodrigues, Abhijit Vasantrao Kadam, Paul Kumaran Paramasivam, Sailaja Kambhampati, Ariarathinam Newtonraj, Natarajan Alangudi Palaniappan, S Devarajulu Reddy, Sourin Bhuniya, Bijaya Kumar Mishra, Ashwini Shete, Luke Elizabeth Hanna, Dipendra Kumar Mitra, Samiran Panda, Randeep Guleria, Srikanth Tripathy, Neelam Roy, George D'Souza, S K Tripathy, Kiran Katoch, Ravindra M Pandey, Seema Sah, Manisha Kashyap, Vinay Telasey, Meenakshi Bakshi, Nitya Wadhwa, Abdul Mabood Khan, Raman R Gangakhedkar, Rajni Rani

BMJ 393 e085716

PMID41962942
PMCIDPMC13063398
DOI10.1136/bmj-2025-085716
发表日期2026-04-10
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig 1:图注未提示 KM 曲线;Fig 2:CONSORT/入组流程图;Fig 3:非 KM 图;Fig 4:图注未提示 KM 曲线;Fig 5:非 KM 图。
摘要

摘要

OBJECTIVE: To evaluate the safety and efficacy of VPM1002 and Immuvac in reducing the incidence of microbiologically confirmed tuberculosis (TB; pulmonary TB and extrapulmonary TB), development of latent TB infection, and immunogenicity. DESIGN: Phase 3 randomised clinical trial (PreVenTB trial). SETTING: 18 sites across six states of India. PARTICIPANTS: 12 717 healthy household contacts (aged ≥6 years) of patients with a smear positive TB test. INTERVENTIONS: Participants were randomly assigned in a 1:1:1 ratio (using block randomisation with variable sample size) to receive an intradermal injection of VPM1002, Immuvac, or placebo in both arms. After one month, a second dose was administered in one arm to 11 829 healthy participants. OUTCOME MEASURES: The primary outcome was efficacy against confirmed TB (pulmonary TB and extrapulmonary TB) over 38 months of follow-up. Secondary outcomes were development of latent TB infection, adverse and serious adverse events, efficacy in predefined age groups, and immunogenicity. Exploratory outcomes were efficacy when considering tuberculin skin test status, and post hoc analyses of efficacy in participants aged 6-14 and according to body mass index. RESULTS: 252 and 227 participants developed microbiologically confirmed TB in modified intention-to-treat and per protocol groups, respectively. The per protocol analysis showed 65 (1.68%), 80 (2.09%), and 82 (2.13%) participants developed TB in the VPM1002, Immuvac, and placebo groups, respectively. Of these, 12 (0.31%), 16 (0.42%), and 24 (0.62%) developed extrapulmonary TB in the VPM1002, Immuvac, and placebo groups, respectively. In the per protocol analysis, VPM1002 showed vaccine efficacy of 21.4% (95% confidence interval (CI) -8.9% to 43.2%), 19.5% (-14.6% to 43.4%), and 50.4% (0.8% to 75.2%) against all TB, pulmonary TB, and extrapulmonary TB, respectively. Immuvac showed vaccine efficacy of 33.2% (-25.9% to 64.5%) against extrapulmonary TB. VPM1002 and Immuvac showed vaccine efficacy of 64.9% (-2% to 90.1%) and 66.3% (1.9% to 90.5%) against extrapulmonary TB in participants with tuberculin skin test positivity. Both vaccines were well tolerated with mild local reactions in about a third of participants. VPM1002 and Immuvac induced Mycobacterium tuberculosis specific polyfunctional CD4+ T cells. Post hoc analyses showed vaccine efficacy of 64.6% (95% CI 16.3% to 85.1%) against all forms of TB, 62.1% (3.0% to 85.2%) against pulmonary TB, and 77.6% (-3.7% to 95.2%) against extrapulmonary TB in participants aged 6-14 years in the VPM1002 group. CONCLUSIONS: Both vaccines were safe but did not show any efficacy against all forms of microbiologically confirmed TB or pulmonary TB. VPM1002 showed considerable efficacy against extrapulmonary TB. Both vaccines showed efficacy against extrapulmonary TB in participants who had a positive tuberculin skin test. TRIAL REGISTRATION: Clinical Trials Registry India CTRI/2019/01/017026.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Vaccine schedule. VPM1002: for first dose, 0.1 mL (2.8×10 5 colony forming units) of vaccine was administered in one arm and 0.1 mL of placebo in the other arm; for second dose (week 4), 0.1 mL of placebo was administered in one arm. Immuvac: for first dose, 0.1 mL of vaccine was administered in each arm (0.2 mL, 1×10 9 bacilli); for second dose (week 4), 0.1 mL (0.5×10 9 bacilli) of vaccine was given in one arm. Placebo: for first dose, 0.1 mL of placebo was administered in each arm; for second dose (week 4), 0.1 mL of placebo was given in one arm 8
非 KM Figure
Fig 2CONSORT (consolidated standards of reporting trials) diagram showing participant numbers screened and enrolled for vaccine trial. Intention-to-treat analysis comprised randomised participants with at least one dose of vaccine or placebo. Modified intention-to-treat analysis included randomised participants with at least one dose and follow-up beyond two months (visit 6), excluding those with co-prevalent tuberculosis (TB). Per protocol analysis included participants from modified intention-to treat analysis, excluding those who did not receive second dose or did not receive it within required period
非 KM Figure
Fig 3Kaplan-Meier plots for cumulative hazard of tuberculosis (TB) over 38 months in participants who received VPM1002, Immuvac, or placebo. Upper panel: microbiologically confirmed pulmonary and extrapulmonary TB; middle panel: microbiologically confirmed pulmonary TB; lower panel: microbiologically confirmed extrapulmonary TB
非 KM Figure
Fig 4Bar graphs showing medians with interquartile ranges of polyfunctional CD4 T cells simultaneously expressing IFN-γ and TNF-α (No of cells per million CD4 T cells), IFN-γ and IL-2, IL-2 and TNF-α, and all three cytokines IFN-γ, TNF-α, and IL-2 in peripheral blood mononuclear cells stimulated with whole cell lysates of Mycobacterium tuberculosis in participants administered VPM1002, Immuvac, and placebo. Upper panel: polyfunctional CD4 T cells in VPM1002 group compared with placebo. CD4 T cells expressing IFN-γ+IL-2 and IL-2+TNF-α were significantly higher in numbers in VPM1002 group at two months after vaccination than placebo. CD4 T cells expressing all three cytokines were significantly increased in VPM1002 group six months after vaccination compared with placebo. Lower panel: polyfunctional CD4 T cells in Immuvac group compared with placebo. CD4 T cells expressing IFN-γ and TNF-α were significantly enhanced at six months in Immuvac group compared with placebo. Although CD4 T cells expressing all three cytokines were increased in Immuvac group, the difference was not statistically significant. 0A, 2A, 6A represent day 0, two months, and six months after vaccination with VPM1002; 0B, 2B, 6B represent day 0, two months, and six months after vaccination with Immuvac; 0C, 2C, 6C represent day 0, two months, and six months after placebo. IFN, interferon; IL, interleukin; TNF, tumour necrosis factor
非 KM Figure
Fig 5Kaplan-Meier plots for cumulative hazard of microbiologically confirmed tuberculosis (TB) over 38 months in participants aged 6 to <14 years who received VPM1002, Immuvac, or placebo. Upper panel: microbiologically confirmed pulmonary and extrapulmonary TB; middle panel: microbiologically confirmed pulmonary TB; lower panel: microbiologically confirmed extrapulmonary TB
非 KM Figure